Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model

Pharmaceutical Research

Volumn 32, Issue 10, 2015, Pages 3269-3281

  Zhao, Jie ^a   Cao, Yanguang ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

allometric scaling; monoclonal antibody; second generation mPBPK

Indexed keywords

AB 02; BELIMUMAB; BEMEGRIDE; BEVACIZUMAB; CANAKINUMAB; DACETUZUMAB; ERLIZUMAB; FELVIZUMAB; MONOCLONAL ANTIBODY; RILOTUMUMAB; RITUXIMAB; SB 249147; TREBANANIB; UNCLASSIFIED DRUG;

ALLOMETRY; ANALYSIS; ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; BLOOD VOLUME; BODY WEIGHT; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXTRAVASATION; ENDOTHELIUM; HUMAN; JOINT ANALYSIS; LYMPH FLOW; MAXIMUM PLASMA CONCENTRATION; MODEL; MPBPK MODEL; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STATISTICAL PARAMETERS; THORACIC DUCT; TISSUE DISTRIBUTION; ALGORITHM; ANIMAL; BIOLOGICAL MODEL; KINETICS; PHYSIOLOGY;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; KINETICS; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

EID: 84942293227     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1703-5     Document Type: Article

References (35)

1. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61-6.
2. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58.
3. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75(11):1028-40.
4. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos. 2010;31(4):253-63.
5. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp Biochem Physiol C Comp Pharmacol Toxicol. 1992;103(2):249-53.
6. Duconge J, Fernandez-Sanchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos. 2004;25(4):177-86.
7. Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet. 1984;9(2):177-83.
8. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica; the fate of foreign compounds in biological systems. 1996;26(9):887-95.
9. Lave T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet. 1999;36(3):211-31.
10. Bischoff KB, Dedrick RL, Zaharko DS. Preliminary model for methotrexate pharmacokinetics. J Pharm Sci. 1970;59(2):149-54.
11. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517-28.
12. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55(20):4611-22.
13. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol. 2008;8(3):401-13.
14. Mann S, Droz PO, Vahter M. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol Appl Pharmacol. 1996;140(2):471-86.
15. Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013;40(5):597-607.
16. Cao Y, Jusko WJ. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2014;41(6):571-80.
17. Cao Y, Jusko WJ. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2014;41(4):375-87.
18. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625-53.
19. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67-86.
20. Rossing N. Intra- and extravascular distribution of albumin and immunoglobulin in man. Lymphology. 1978;11(4):138-42.
21. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984;15(5-6):1071-121.
22. Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev. 2001;50(1-2):157-71.
23. Lindena J, Kupper W, Trautschold I. Catalytic enzyme activity concentration in thoracic duct, liver, and intestinal lymph of the dog, the rabbit, the rat and the mouse. Approach to a quantitative diagnostic enzymology, II. Communication. J Clin Chem Clin Biochem. 1986;24(1):19-33.
24. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-5.
25. Rodionov N. Graph digitizer version 1.9. 2000.
26. D'Argenio DZ, Schumitzky A. ADAPT V user's guide: pharmacokinetic/pharmacodynamic systerm analysis software. Los Angeles: Biomedical Simulations Resorce; 2009.
27. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol. 2008;8(3):477-83.
28. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288(1):371-8.
29. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687-709.
30. Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos. 2005;33(9):1297-303.
31. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol. 2009;49(12):1382-402.
32. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8(11):1351-9.
33. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012;14(3):554-8.
34. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153-63.
35. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861-71.